[14, 15] A recent high-throughput drug screen aimed at uncovering therapeutic strategies in CRC, revealed the essentiality of MCL1, Bcl-2 and Bcl-xL in BRAFMT-driven disease [16]. This evidence concerns the gene MCL1 and colorectal carcinoma.